Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 548 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer
SH APBI RISE: Evaluating the Safety and Efficacy of a Novel IMRT/VMAT-based Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
Who cites it
548 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy of endocrine therapy alone versus endocrine therapy combined with radiotherapy after breast-conserving surgery in older patients with early-stage estrogen receptor-positive breast cancer: a meta-analysis.World journal of surgical oncology · 2026Pooled it
- Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data.Breast cancer (Tokyo, Japan) · 2024Pooled it
- Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials.Radiation oncology (London, England) · 2023Pooled it
- Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature.Annals of surgical oncology · 2023Pooled it
- Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer.Annals of surgical oncology · 2026Trial
- Trial
- Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial.Annals of surgical oncology · 2026Trial
- Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E.BMC cancer · 2025Trial
- Ninety Days of Preoperative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy: Primary Results from the Preoperative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER) Trial.Annals of surgical oncology · 2025Trial
- Ultrahypofractionated partial breast irradiation following oncoplastic surgery: secondary analysis of a phase II trial.Radiation oncology (London, England) · 2025Trial
- Recommendations from the Geriatric Oncology Working Group of the Spanish Society of Radiation Oncology for the treatment of elderly patients with radiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- National trends in dual de-escalation of axillary surgery and adjuvant radiation in early-stage HR+/HER2- breast cancer.Breast cancer research and treatment · 2026Article
- Role of Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer Stratified by Tumor Quadrant Location.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Impact of Omission of Sentinel Lymph Node Surgery on Radiation Treatment in Patients Age 50 and Older with Breast Cancer Treated with Lumpectomy: A Single-Institution Retrospective Review.Annals of surgical oncology · 2026Article
- From Clinical Trial Awareness to Practice: Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.Annals of surgical oncology · 2026Article
- Article
- Evaluation of Surgeon Attitudes Toward Frailty Screening in Breast Oncology Patients.Annals of surgical oncology · 2026Article
- Patient Selection for Partial Breast Irradiation in the Era of Sentinel Lymph Node Biopsy Omission: A Narrative Review.Cancers · 2026Review
- Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older.Breast cancer research and treatment · 2026Article
488 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
purposeTo determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. PATIENTS AND
methodsBetween July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).
resultsMedian follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively.
conclusionWith long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.